Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- MTPC Terminates Joint Development of Roflumilast with Nycomed
February 7, 2011
- Present Industry's Opinions to Office of Medical Innovation: Mr Kawakami
February 7, 2011
- Sunovion Aims at Rapid Market Entry for Latuda by Replacing Existing Products
February 7, 2011
- Hayashibara Applies for Business Revitalization ADR
February 7, 2011
- FJPWA Calls For Resumption of Ryukaikon
February 7, 2011
- Takeda, MSD Call For Precautions on Similar Drug Names
February 7, 2011
- Meiji Seika, Fresenius Kabi Ally to Develop Anticancer Generics Business in Japan
February 7, 2011
- NBI's Mirapex Recommended for Approval
February 7, 2011
- Mochida Aims at Sales of ¥10 Bil. with Generics
February 7, 2011
- Making Whole of Japan Large Pharmaceutical Company: Prof. Nakamura
February 7, 2011
- Nichi-Iko to Raise ¥20 Bil. through Public Stock Offerings
February 7, 2011
- Pfizer Aims for Approval of 7 Products Each Year: President Umeda
February 7, 2011
- Gov't Rejects Court-Proposed Compromise in Iressa Lawsuits
February 7, 2011
- Torii Starts PIII Trial of Sublingual Desensitization Therapy for Cedar Pollinosis
February 7, 2011
- No. of Prescriptions Filled by GROWELL Up Sharply Due to Point Granting
January 31, 2011
- Takara Bio to Globally Develop HF10 Licensed from M's Science
January 31, 2011
- Xyzal Ranked No. 1 in GP Market: RepTrack Survey
January 31, 2011
- Takeda, Kyoto Univ. to Collaborate for CNS Drug Discovery
January 31, 2011
- aRigen Licenses Novel Anti-MRSA to GCC in South Korea
January 31, 2011
- Kyowa Kirin Licenses AMG827 from Amgen
January 31, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…